Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.

You may also be interested in...

Genitope Pulls Plug On Cancer Vaccine

FDA wants another Phase III trial with non-Hodgkins lymphoma drug.

Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program

Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts